Clyra Medical Technologies
Clyra Medical Technologies is a healthcare company dedicated to improving lives by developing and commercializing innovative products for wound and skin infection treatment. As a subsidiary of BioLargo, Inc., Clyra focuses on creating safe, effective, and cost-efficient solutions that reduce the need for antibiotics and promote wound healing. Their technology, based on a copper-iodine complex, offers a broad-spectrum antimicrobial effect without known microbial resistance, making it suitable for various healthcare settings.
Industries
Nr. of Employees
small (1-50)
Clyra Medical Technologies
3802 Spectrum Blvd, Suite 115, Tampa, FL 33612
Patents
Systems and methods for reducing contaminants in a portion of a patient
2023-09-19 • US-11759583-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
2023-09-05 • US-11744249-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
2022-10-04 • US-11457632-B1
View DetailsSystems and methods for reducing contaminants in a portion of a patient
2021-08-31 • US-11103657-B2
View Details
Systems and methods for reducing contaminants in a portion of a patient
2023-09-19 • US-11759583-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
2023-09-05 • US-11744249-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
2022-10-04 • US-11457632-B1
View DetailsSystems and methods for reducing contaminants in a portion of a patient
2021-08-31 • US-11103657-B2
View DetailsProducts
Wound irrigation solution (copper-iodine complex) — cleared under FDA 510(k)
A clear, non-irritating wound irrigation formulation based on a copper-iodine complex; indicated for acute and chronic wounds and reported to provide high antimicrobial activity and biofilm reduction with sustained efficacy.
Antimicrobial wound hydrogel (in development)
Hydrogel dressing designed to hydrate and protect acute and chronic wounds while providing antimicrobial activity and odor control.
Super-absorbent pads and antimicrobial dressings (in development)
Highly absorbent pads and dressings impregnated with antimicrobial technology to manage heavy exudate and bodily fluids while providing odor control.
NPWT-compatible irrigation and dressing integration (in development)
Impregnation of antimicrobial technology into dressings for negative pressure wound therapy and use as an irrigation solution compatible with NPWT systems.
Oral rinse for dental hygiene (product under development)
A clear oral rinse based on the copper-iodine complex platform intended for gum health and dental hygiene; described for twice-daily use as a rinse.
Autologous stem-cell-derived wound biogel (acquired technology)
Acquired autologous cell-rich biogel technology intended to support healing of chronic wounds using a patient’s own cells and plasma.
Wound irrigation solution (copper-iodine complex) — cleared under FDA 510(k)
A clear, non-irritating wound irrigation formulation based on a copper-iodine complex; indicated for acute and chronic wounds and reported to provide high antimicrobial activity and biofilm reduction with sustained efficacy.
Antimicrobial wound hydrogel (in development)
Hydrogel dressing designed to hydrate and protect acute and chronic wounds while providing antimicrobial activity and odor control.
Super-absorbent pads and antimicrobial dressings (in development)
Highly absorbent pads and dressings impregnated with antimicrobial technology to manage heavy exudate and bodily fluids while providing odor control.
NPWT-compatible irrigation and dressing integration (in development)
Impregnation of antimicrobial technology into dressings for negative pressure wound therapy and use as an irrigation solution compatible with NPWT systems.
Oral rinse for dental hygiene (product under development)
A clear oral rinse based on the copper-iodine complex platform intended for gum health and dental hygiene; described for twice-daily use as a rinse.
Autologous stem-cell-derived wound biogel (acquired technology)
Acquired autologous cell-rich biogel technology intended to support healing of chronic wounds using a patient’s own cells and plasma.
Expertise Areas
- Advanced wound care product development
- Antimicrobial formulation and biofilm control
- Preclinical GLP and ISO biocompatibility testing
- Regulatory submissions (FDA 510(k))
Key Technologies
- Copper-iodine complex advanced oxidation chemistry
- Antimicrobial oxidative formulations
- Hydrogel and impregnated dressing technologies
- Biofilm assay and control methods
Key People
Chief Executive Officer
Chairman of the Board
Director
Director
Director
Chief Operating Officer
Chief Executive Officer
Chairman of the Board
Director
Director
Director
Chief Operating Officer
News & Updates
Clyra's first wound management product has received 510(k) clearance from the FDA, marking a significant milestone in their product development.
Clyra's first wound management product has received 510(k) clearance from the FDA, marking a significant milestone in their product development.